Rezolute, Inc. (NASDAQ:RZLT) Shares Sold by Marshall Wace LLP

Marshall Wace LLP decreased its position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 25.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 843,144 shares of the company's stock after selling 285,409 shares during the quarter. Marshall Wace LLP owned 1.46% of Rezolute worth $4,131,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in Rezolute during the third quarter worth $42,000. MML Investors Services LLC acquired a new position in shares of Rezolute during the 3rd quarter worth $57,000. Charles Schwab Investment Management Inc. boosted its position in shares of Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after buying an additional 9,000 shares in the last quarter. Virtu Financial LLC grew its stake in Rezolute by 58.0% in the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock valued at $126,000 after acquiring an additional 9,551 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in Rezolute during the 4th quarter valued at about $277,000. Institutional investors and hedge funds own 82.97% of the company's stock.

Rezolute Price Performance

RZLT stock traded down $0.09 during midday trading on Monday, hitting $3.76. The stock had a trading volume of 842,907 shares, compared to its average volume of 593,271. Rezolute, Inc. has a 12-month low of $2.22 and a 12-month high of $6.19. The firm has a market cap of $227.61 million, a PE ratio of -3.08 and a beta of 0.97. The company's 50-day moving average price is $3.36 and its 200 day moving average price is $4.44.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. As a group, sell-side analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current year.

Insider Activity

In other news, Director Wladimir Hogenhuis acquired 10,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the acquisition, the director now directly owns 77,267 shares in the company, valued at approximately $363,154.90. This represents a 14.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Nevan C. Elam bought 12,302 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was purchased at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the transaction, the chief executive officer now directly owns 224,119 shares in the company, valued at approximately $638,739.15. This trade represents a 5.81 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 39,060 shares of company stock valued at $130,694 in the last 90 days. 18.39% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently commented on RZLT shares. JMP Securities increased their price target on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research note on Monday. Craig Hallum raised Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Finally, Guggenheim reissued a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $26.43.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.